Testosterone therapy in men with prostate cancer: Scientific and ethical considerations

Journal of Urology

Volumn 189, Issue 1 SUPPL, 2013, Pages

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

androgens; hypogonadism; prostatic neoplasms; testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

BRACHYTHERAPY; CANCER GROWTH; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDICAL ETHICS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 84870909367     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.028     Document Type: Review

References (50)

1. A. Morgentaler Testosterone replacement therapy and prostate cancer Urol Clin North Am 34 2007 555
2. E.L. Rhoden, M.A. Averback, P.E. Teloken Androgen replacement in men undergoing treatment for prostate cancer J Sex Med 5 2008 2202
3. A. Morgentaler Testosterone and prostate cancer: an historical perspective on a modern myth Eur Urol 50 2006 935
4. J.M. Kaufman, R.J. Graydon Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men J Urol 172 2004 920
5. P.K. Agarwal, M.G. Oefelein Testosterone replacement therapy after primary treatment for prostate cancer J Urol 173 2005 533
6. M.F. Sarosdy Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy Cancer 109 2007 536
7. Morgentaler A: Two years of testosterone therapy associated with decline in serum prostate-specific antigen in a man with untreated prostate cancer. Unpublished data.
8. C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A.M. Matsumoto, P.J. Snyder Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone density in hypogonadal men J Clin Endocrinol Metab 89 2004 2085
9. S. Bhasin, G.R. Cunningham, F.J. Hayes, A.M. Matsumoto, P.J. Snyder, R.S. Swerdloff Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline J Clin Endocrinol Metab 91 2006 1995
10. A. Morgentaler Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer J Sex Med 5 2008 1834
11. C. Huggins, C.V. Hodges Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
12. G.R. Prout, W.R. Brewer Response of men with advanced prostatic carcinoma to exogenous administration of testosterone Cancer 20 1967 1871
13. J.E. Fowler Jr, W.F. Whitmore Jr The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J Urol 126 1981 372
14. G.J. Bubley Is the flare phenomenon clinically significant? Urology 58 suppl 2001 5
15. C.T. Liverman, D.G. Blazer Testosterone and Aging: Clinical Research Directions 2004 National Academies Press Washington D. C.
16. E.L. Rhoden, A. Morgentaler Risks of testosterone-replacement therapy and recommendations for monitoring N Engl J Med 350 2004 482
17. D.J. Tindall, R.S. Rittmaster The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer J Urol 179 2008 1235
18. A. Morgentaler, A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen stimulation of prostate cancer Eur Urol 2008 Epub ahead of print
19. A.M. Traish, D.F. Williams, N.D. Hoffman, H.H. Wotan Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates Prog Clin Biol Res 262 1988 145
20. S.M. Ho, D. Damassa, P.W. Kwan, H.S. Seto, I. Leav Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats J Androl 6 1985 279
21. M. Bologna, P. Muzi, L. Biordi, C. Festuccia, C. Vicentini Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro Urology 45 1995 282
22. J.T. Arnold, H. Le, K.K. McFann, M.R. Blackman Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells Am J Physiol Endocrinol Metab 288 2005 E573
23. J.M. Kuhn, T. Billebaud, H. Navratil, A. Moulonguet, J. Fiet, P. Grise Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide) N Engl J Med 321 1989 413
24. K. Tomera, D. Gleason, M. Gittelman, W. Moseley, N. Zinner, M. Murdoch The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer J Urol 165 2001 1585
25. J.P. Weber, J.E. Oesterling, C.A. Peters, A.W. Partin, D.W. Chan, P.C. Walsh The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia J Urol 141 1989 987
26. L.S. Marks, G.L. Andriole, J.M. Fitzpatrick, C.C. Schulman, C.G. Roehrborn The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations J Urol 176 2006 868
27. J.R. Monath, D.L. McCullough, L.J. Hart, J.P. Jarow Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen Urology 46 1995 58
28. B.A. Mohr, H.A. Feldman, L.A. Kalish, C. Longcope, J.B. McKinlay Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study Urology 57 2001 930
29. C.S. Cooper, P.J. Perry, A.E. Sparks, J.H. MacIndoe, W.R. Yates, R.D. Williams Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 159 1998 441
30. S. Bhasin, T.W. Storer, N. Berman, C. Callegari, B. Clevenger, J. Phillips The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men N Engl J Med 335 1996 1
31. C. Steidle, S. Schwartz, K. Jacoby, T. Sebree, T. Smith, R. Bachand AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function J Clin Endocrinol Metab 88 2003 2673
32. O.M. Calof, A.B. Singh, M.L. Lee, A.M. Kenny, R.J. Urban, J.L. Tenover Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials J Gerontol A Biol Sci Med Sci 60 2005 1451
33. E.L. Rhoden, A. Morgentaler Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy Int J Impot Res 18 2006 201
34. J.K. Parsons, H.B. Carter, E.A. Platz, E.J. Wright, P. Landis, E.J. Metter Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy Cancer Epidemiol Biomarkers Prev 14 2005 2257
35. Endogenous Hormones Prostate Cancer Collaborative Group A.W. Roddam, N.E. Allen, P. Appleby, T.J. Key Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170
36. A. Morgentaler Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship Eur Urol 52 2007 623
37. S. Yamamoto, J. Yonese, S. Kawakami, Y. Ohkubo, M. Tatokoro, Y. Komai Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy Eur Urol 52 2007 696
38. M. Khera, J. Colen, E. Grober, B.B. Najari, L. Murthy, D.J. Lamb The safety and efficacy of testosterone replacement therapy following radical prostatectomy J Urol 177 suppl 2007 384 abstract 1164
39. O. Nabulsi, R. Tal, G. Gotto, J. Narus, L. Goldenberg, J.P. Mulhall Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy J Urol 179 suppl 2008 406 abstract 1181
40. H.H. Davila, C.N. Arison, M.K. Hall, R. Salup, J.L. Lockhart, R.E. Carrion Analysis of the PSA response after testosterone supplementation in patients who have previously received management for their localized prostate cancer J Urol 179 suppl 2008 428 abstract 1247
41. I. Sasagawa, T. Nakada, Y. Kubota, T. Sawamura, K. Izumiya Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation Int Urol Nephrol 27 1995 769
42. A. Morgentaler, E.L. Rhoden Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less Urology 68 2006 1263
43. L.S. Marks, N.A. Mazer, E. Mostaghel, D.L. Hess, F.J. Dorey, J.I. Epstein Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2006 2351
44. I.M. van Oort, D.E. Kok, L.A. Kiemeney, C.A. Hulsbergen-van de Kaa, J.A. Witjes A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant." Urol Oncol 2008 Epub ahead of print
45. E.L. Rhoden, A. Morgentaler Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia J Urol 170 2003 2348
46. A. Morgentaler, C.O. Bruning 3rd, W.C. DeWolf Incidence of occult prostate cancer among men with low total or free serum testosterone JAMA 276 1996 1904
47. C.P. Chuu, R.A. Hiipakka, J. Fukuchi, J.M. Kokontis, S. Liao Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice Cancer Res 65 2005 2082
48. R.S. Svatek, M.J. Shulman, E.A. Benaim, T.E. Rogers, V. Margulis Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis J Urol 179 2008 2192
49. F.D. Gaylis, D.W. Lin, J.M. Ignatoff, C.L. Amling, R.F. Tutrone, D.J. Cosgrove Prostate cancer in men using testosterone supplementation J Urol 174 2005 534
50. I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, L.G. Ford The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215